Nanite
Nanite is a biotechnology company pioneering the future of genetic drug delivery with its AI-driven platform, SAYER. This platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class, tissue-specific, non-viral polymer nanoparticles (PNPs) for gene therapy. Nanite's approach offers advantages over viral vectors and lipid nanoparticles, overcoming historical limitations in understanding polymer-biology interactions. The company focuses on engineering precision delivery vectors for a broad range of modalities and indications, including collaborations for HIV gene therapy with the Bill & Melinda Gates Foundation and targeted lung delivery for Cystic Fibrosis with the Cystic Fibrosis Foundation. Nanite is comprised of a diverse team of biologists, chemists, engineers, and machine learning experts dedicated to solving significant challenges in genetic medicine.
Nanite
Nanite is a biotechnology company pioneering the future of genetic drug delivery with its AI-driven platform, SAYER. This platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class, tissue-specific, non-viral polymer nanoparticles (PNPs) for gene therapy. Nanite's approach offers advantages over viral vectors and lipid nanoparticles, overcoming historical limitations in understanding polymer-biology interactions. The company focuses on engineering precision delivery vectors for a broad range of modalities and indications, including collaborations for HIV gene therapy with the Bill & Melinda Gates Foundation and targeted lung delivery for Cystic Fibrosis with the Cystic Fibrosis Foundation. Nanite is comprised of a diverse team of biologists, chemists, engineers, and machine learning experts dedicated to solving significant challenges in genetic medicine.
TL;DR
Founded: 2021
Headquarters: Boston, Massachusetts
Focus: AI-driven non-viral polymer nanoparticle (PNP) gene delivery
Platform: SAYER (AI-driven polymer design + multiplexed in vivo screening)
Notable investors: Bill & Melinda Gates Foundation; Cystic Fibrosis Foundation; Zetta Venture Partners; Arkitekt Ventures
Company Overview
Problem Domain
Gene therapy delivery — engineering non-viral delivery vectors that are tissue-specific, low-toxicity, and re-dosable.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Grant announced May 8, 2024
Seed round reported in 2023
Seed round reported in 2023
Investor Signal
“Funded by philanthropic foundations and early-stage VCs, including the Bill & Melinda Gates Foundation and the Cystic Fibrosis Foundation alongside Zetta Venture Partners and Arkitekt Ventures”